| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension.
|
Circ Res
|
2011
|
1.31
|
|
2
|
Rational design of α-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: utilization of charge, 'specificity determinants,' total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio.
|
Chem Biol Drug Des
|
2011
|
1.07
|
|
3
|
Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes.
|
FASEB J
|
2002
|
1.06
|
|
4
|
Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension.
|
Sci Transl Med
|
2013
|
1.05
|
|
5
|
Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
|
Cancer Res
|
2008
|
0.99
|
|
6
|
Computational discovery of novel low micromolar human pregnane X receptor antagonists.
|
Mol Pharmacol
|
2008
|
0.98
|
|
7
|
The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction.
|
Cardiovasc Res
|
2004
|
0.92
|
|
8
|
B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation.
|
J Pharmacol Exp Ther
|
2007
|
0.90
|
|
9
|
Bradykinin-related compounds as new drugs for cancer and inflammation.
|
Can J Physiol Pharmacol
|
2002
|
0.87
|
|
10
|
A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells.
|
Peptides
|
2010
|
0.86
|
|
11
|
Methylprednisolone causes matrix metalloproteinase-dependent emphysema in adult rats.
|
Am J Respir Crit Care Med
|
2003
|
0.85
|
|
12
|
Vascular smooth muscle contractility assays for inflammatory and immunological mediators.
|
Int Immunopharmacol
|
2010
|
0.85
|
|
13
|
Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B₂ receptor cycling.
|
Pharmacol Res
|
2013
|
0.85
|
|
14
|
BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis.
|
Clin Cancer Res
|
2008
|
0.84
|
|
15
|
Prolonged signalling and trafficking of the bradykinin B2 receptor stimulated with the amphibian peptide maximakinin: insight into the endosomal inactivation of kinins.
|
Pharmacol Res
|
2011
|
0.84
|
|
16
|
Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy.
|
Peptides
|
2005
|
0.84
|
|
17
|
A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.
|
Can J Physiol Pharmacol
|
2002
|
0.82
|
|
18
|
Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
|
Peptides
|
2005
|
0.82
|
|
19
|
Fluorescent ligands of the bradykinin B1 receptors: pharmacologic characterization and application to the study of agonist-induced receptor translocation and cell surface receptor expression.
|
J Pharmacol Exp Ther
|
2009
|
0.81
|
|
20
|
Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors.
|
Br J Pharmacol
|
2009
|
0.81
|
|
21
|
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.
|
Proc Natl Acad Sci U S A
|
2002
|
0.80
|
|
22
|
A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor.
|
Mol Pharmacol
|
2006
|
0.80
|
|
23
|
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
|
Clin Cancer Res
|
2002
|
0.80
|
|
24
|
A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging.
|
Peptides
|
2008
|
0.79
|
|
25
|
Characterization of the B2 receptor and activity of bradykinin analogs in SHP-77 cell line by Cytosensor microphysiometer.
|
Chem Biol Interact
|
2004
|
0.77
|
|
26
|
Preparative reversed-phase liquid chromatography of peptides. Isocratic two-step elution system for high loads on analytical columns.
|
J Chromatogr A
|
2002
|
0.77
|
|
27
|
Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
|
FEBS J
|
2010
|
0.76
|
|
28
|
Bradykinin antagonists as new drugs for prostate cancer.
|
Int Immunopharmacol
|
2002
|
0.76
|
|
29
|
Evidence for bradykinin as a stimulator of thirst.
|
Am J Physiol Renal Physiol
|
2004
|
0.76
|
|
30
|
Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta.
|
J Pharmacol Exp Ther
|
2005
|
0.76
|
|
31
|
Synthesis and biological evaluation of analogues of the peptaibol ampullosporin A.
|
J Med Chem
|
2002
|
0.76
|
|
32
|
Changes in amino-terminal portion of human B2 receptor selectively increase efficacy of synthetic ligand HOE 140 but not of cognate ligand bradykinin.
|
Am J Physiol Heart Circ Physiol
|
2003
|
0.75
|
|
33
|
Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity.
|
J Biomol Struct Dyn
|
2002
|
0.75
|
|
34
|
Discovery and therapeutic potential of kinin receptor antagonists.
|
Expert Opin Drug Discov
|
2012
|
0.75
|
|
35
|
New lung cancer drugs from bradykinin antagonists.
|
Chest
|
2004
|
0.75
|
|
36
|
Stereoselective determination of the epimer mixtures of itraconazole in human blood plasma using HPLC and fluorescence detection.
|
Chirality
|
2011
|
0.75
|
|
37
|
An in vitro reconstitution system to address the mechanism of the vascular expression of the bradykinin B₁ receptor in response to angiotensin converting enzyme inhibition.
|
Vascul Pharmacol
|
2011
|
0.75
|